179 related articles for article (PubMed ID: 30897712)
1. The Relationship between Eicosanoid Levels and Serum Levels of Metabolic and Hormonal Parameters Depending on the Presence of Metabolic Syndrome in Patients with Benign Prostatic Hyperplasia.
Grzesiak K; Rył A; Stachowska E; Słojewski M; Rotter I; Ratajczak W; Sipak O; Piasecka M; Dołęgowska B; Laszczyńska M
Int J Environ Res Public Health; 2019 Mar; 16(6):. PubMed ID: 30897712
[No Abstract] [Full Text] [Related]
2. Comparison between selected hormone and protein levels in serum and prostate tissue homogenates in men with benign prostatic hyperplasia and metabolic disorders.
Grzesiak K; Rył A; Baranowska-Bosiacka I; Rotter I; Dołęgowska B; Słojewski M; Sipak-Szmigiel O; Ratajczak W; Lubkowska A; Metryka E; Piasecka M; Laszczyńska M
Clin Interv Aging; 2018; 13():1375-1382. PubMed ID: 30122909
[TBL] [Abstract][Full Text] [Related]
3. Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels.
Rył A; Rotter I; Grzywacz A; Małecka I; Skonieczna-Żydecka K; Grzesiak K; Słojewski M; Szylińska A; Sipak-Szmigiel O; Piasecka M; Walczakiewicz K; Laszczyńska M
Int J Environ Res Public Health; 2017 Oct; 14(11):. PubMed ID: 29084161
[No Abstract] [Full Text] [Related]
4. Influence of metabolic syndrome on the relationship between fatty acids and the selected parameters in men with benign prostatic hyperplasia.
Grzesiak K; Rył A; Ratajczak W; Stachowska E; Rotter I; Słojewski M; Sipak O; Walczakiewicz K; Laszczyńska M
Aging (Albany NY); 2019 Mar; 11(5):1524-1536. PubMed ID: 30867336
[TBL] [Abstract][Full Text] [Related]
5. Alterations in fecal short chain fatty acids (SCFAs) and branched short-chain fatty acids (BCFAs) in men with benign prostatic hyperplasia (BPH) and metabolic syndrome (MetS).
Ratajczak W; Mizerski A; Rył A; Słojewski M; Sipak O; Piasecka M; Laszczyńska M
Aging (Albany NY); 2021 Apr; 13(8):10934-10954. PubMed ID: 33847600
[TBL] [Abstract][Full Text] [Related]
6. 5-Lipooxygenase Derivatives as Serum Biomarkers of a Successful Dietary Intervention in Patients with NonAlcoholic Fatty Liver Disease.
Banaszczak M; Maciejewska D; Drozd A; Ryterska K; Milc DJ; Raszeja-Wyszomirska J; Wunsch E; González-Muniesa P; Stachowska E
Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32028646
[No Abstract] [Full Text] [Related]
7. Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome.
Ozer K; Horsanali MO; Gorgel SN; Horsanali BO; Ozbek E
Urol Int; 2017; 98(4):466-471. PubMed ID: 27464069
[TBL] [Abstract][Full Text] [Related]
8. The Relationship between Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms and Mean Platelet Volume: The Role of Metabolic Syndrome.
Zhao S; Tang J; Shao S; Yan Y
Urol Int; 2016; 96(4):449-58. PubMed ID: 26745140
[TBL] [Abstract][Full Text] [Related]
9. Impact of metabolic status on the association of serum vitamin D with hypogonadism and lower urinary tract symptoms/benign prostatic hyperplasia.
Park SG; Yeo JK; Cho DY; Park MG
Aging Male; 2018 Mar; 21(1):55-59. PubMed ID: 28414251
[TBL] [Abstract][Full Text] [Related]
10. Relationship between predictors of the risk of clinical progression of benign prostatic hyperplasia and metabolic syndrome in men with moderate to severe lower urinary tract symptoms.
Kwon H; Kang HC; Lee JH
Urology; 2013 Jun; 81(6):1325-9. PubMed ID: 23602796
[TBL] [Abstract][Full Text] [Related]
11. The impacts of metabolic syndrome and lifestyle on the prevalence of benign prostatic hyperplasia requiring treatment: historical cohort study of 130 454 men.
Yoo S; Oh S; Park J; Cho SY; Cho MC; Jeong H; Son H
BJU Int; 2019 Jan; 123(1):140-148. PubMed ID: 30125452
[TBL] [Abstract][Full Text] [Related]
12. Tissue immunoexpression of IL-6 and IL-18 in aging men with BPH and MetS and their relationship with lipid parameters and gut microbiota-derived short chain fatty acids.
Ratajczak W; Laszczyńska M; Rył A; Dołęgowska B; Sipak O; Stachowska E; Słojewski M; Lubkowska A
Aging (Albany NY); 2023 Oct; 15(20):10875-10896. PubMed ID: 37847180
[TBL] [Abstract][Full Text] [Related]
13. Metabolic syndrome and benign prostatic hyperplasia: association or coincidence?
Rył A; Rotter I; Miazgowski T; Słojewski M; Dołęgowska B; Lubkowska A; Laszczyńska M
Diabetol Metab Syndr; 2015; 7():94. PubMed ID: 26516352
[TBL] [Abstract][Full Text] [Related]
14. The single nucleotide polymorphism rs700518 is an independent risk factor for metabolic syndrome and benign prostatic hyperplasia (MetS-BPH).
Chen ZP; Yan Y; Chen CJ; Li M; Chen C; Zhao SC; Song T; Liu T; Zou CH; Xu Q; Li X
Andrology; 2018 Jul; 6(4):568-578. PubMed ID: 29873201
[TBL] [Abstract][Full Text] [Related]
15. Benign Prostatic Hyperplasia, Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease: Is Metaflammation the Link?
Russo GI; Cimino S; Castelli T; Favilla V; Gacci M; Carini M; Condorelli RA; La Vignera S; Calogero AE; Motta F; Puzzo L; Caltabiano R; Morgia G
Prostate; 2016 Dec; 76(16):1528-1535. PubMed ID: 27458062
[TBL] [Abstract][Full Text] [Related]
16. Hormone concentration, metabolic disorders and immunoexpression of androgen and estrogen-alpha receptors in men with benign prostatic hyperplasia and testosterone deficiency syndrome.
Ryl A; Rotter I; Slojewski M; Dolegowska B; Grabowska M; Baranowska-Bosiacka I; Laszczynska M
Folia Histochem Cytobiol; 2015; 53(3):227-35. PubMed ID: 26400665
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of metabolic syndrome and benign prostatic hyperplasia in Chinese patients.
Zou C; Gong D; Fang N; Fan Y
World J Urol; 2016 Feb; 34(2):281-9. PubMed ID: 26119349
[TBL] [Abstract][Full Text] [Related]
18. [FEATURES OF CLINICAL COURSE AND MORPHOMETRIC PARAMETERS OF BENIGN PROSTATIC HYPERPLASIA IN MEN WITH METABOLIC SYNDROME AND ANDROGEN DEFICIENCY].
Tyuzikov IA; Grekov EA; Kalinchenko SY
Urologiia; 2015; (5):66-9. PubMed ID: 26859941
[TBL] [Abstract][Full Text] [Related]
19. Eicosanoids in Nonalcoholic Fatty Liver Disease (NAFLD) Progression. Do Serum Eicosanoids Profile Correspond with Liver Eicosanoids Content during NAFLD Development and Progression?
Maciejewska D; Drozd A; Skonieczna-Żydecka K; Skórka-Majewicz M; Dec K; Jakubczyk K; Pilutin A; Stachowska E
Molecules; 2020 Apr; 25(9):. PubMed ID: 32349225
[TBL] [Abstract][Full Text] [Related]
20. The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome.
Park YW; Kim SB; Kwon H; Kang HC; Cho K; Lee KI; Kim YJ; Lee JH
Urology; 2013 Sep; 82(3):674-9. PubMed ID: 23850334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
